PYM50028

T his meeting was my first visit to San Diego – if I'd have known better I would have brought my wetsuit and surfboard (I've… Expand

Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but… Expand

The purpose of this paper is to study the effect of smilagenin (SMI) (PYM50028), a sapogenin compound originally identified from… Expand

Parkinson's disease is a common, progressive, debilitating disease with substantial physical, psychological and social… Expand

Currently the mainstay of Parkinson's disease (PD) therapy is the pharmacological replacement of the loss of the dopaminergic… Expand

The XVIII World Federation of Neurology (WFN) World Congress on Parkinson's Disease and Related Disorders, held in Miami, FL, USA… Expand

The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new… Expand

Many experimental data support the enhancement of neurotrophic factors as a means to modify neurodegeneration in Parkinson's… Expand

The meeting covered many aspects of the use of natural products in drug discovery and development. The historical and current… Expand